This three-year rare disease study was being conducted at 75 study sites throughout the United States, Canada, Europe, and Australia. The study required a 13-month commitment from patients and had a rigorous visit calendar for the first three months of treatment, thus the sponsor was seeking assistance with patient travel and coordination.

Get Your Copy Now